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Longitudinal biomonitoring studies can provide unique information on how human 27 
concentrations change over time, but have so far not been conducted for per- and polyfluoroalkyl 28 
substances (PFASs) in a background exposed population.  29 
Objectives  30 
Determine: i) serum PFAS time trends on an individual level; ii) relative compositions and 31 
correlations between different PFASs; and iii) assess selected PFAS concentrations with respect 32 
to periodic (calendar year), age and birth cohort (APC) effects. 33 
Methods 34 
Serum was sampled from the same 53 men in 1979, 1986, 1994, 2001 and 2007 in Northern 35 
Norway and analysed for 10 PFASs. APC effects were assessed by graphical and mixed effect 36 
analyses. 37 
Results  38 
The median concentrations of PFOS and PFOA increased five-fold from 1979 to 2001 and 39 
decreased by 26% and 23%, respectively, from 2001 to 2007. The concentrations of 40 
perfluorooctanoic acid (PFOA) and perfluorooctane sulphonic acid (PFOS) peaked during 1994-41 
2001 and 2001, respectively, whereas perfluorohexane sulphonic acid (PFHxS) increased to 42 
2001, but did not demonstrate a decrease between 2001 and 2007. Perfluorononanoic acid 43 
(PFNA), perfluorodecanoic acid (PFDA), and perfluoroundecanoic acid (PFUnDA) displayed 44 
increasing trends throughout the entire study period (1979-2007). Although PFOS comprised 45 
dominating and stable proportions of PFAS burdens during these years, the contributions from 46 
PFOA and PFHxS were considerable. The evaluation of APC effects demonstrated that calendar 47 
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year was the dominating influence on concentrations of PFOA, PFUnDA, and PFOS, although 48 
time-variant and weaker associations with age/birth cohort were indicated. 49 
Conclusions  50 
The concentration changes of 10 PFASs in the repeated measurements from 1979 to 2007 51 
demonstrated divergent time trends between the different PFASs.  The temporal trends of PFASs 52 
in human serum during these 30 years reflect the overall trends in historic production and use, 53 
although global transport mechanisms and bioaccumulation potential of the different PFASs 54 
together with a varying extent of consumer exposure influenced the observed trends. Sampling 55 
year was the strongest descriptor of PFOA, PFUnDA and PFOS concentrations, and the calendar-56 
year trends were apparent for all birth year quartiles. Discrepancies between the trends in this 57 
current longitudinal study and previous cross-sectional studies were observed and presumably 58 
reflect the different study designs and population characteristics. 59 
 60 
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sulfonic acid; PFHxA, Perfluorohexanoic acid; PFHxS, Perfluorohexane sulfonic acid; PFPeA, 72 
Perfluoropentanoic acid, PFNA, Perfluorononanoic acid; PFOA, Perfluorooctanoic acid; PFOS, 73 
Perfluorooctane sulfonic acid; PFSAs, Perfluoroalkyl sulphonic acids; PFUnDA, 74 
Perfluoroundecanoic acid; POP, Persistent organic pollutant; SRM, Standard reference material.  75 
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1. Introduction 78 
Production and use of per- and polyfluoroalkyl substances (PFASs) started in the 1950s and 79 
increased considerably during the 1970s (Paul et al., 2009; Prevedouros et al., 2006). PFASs 80 
continue to be in high demand today due to their widespread use in industrial and consumer 81 
product applications (Buck et al., 2011). Two major PFAS groups are the perfluoroalkyl 82 
carboxylic acids (PFCAs) and the perfluoroalkyl sulphonic acids (PFSAs) (Buck et al., 2011), of 83 
which perfluorooctanoic acid (PFOA) and perfluorooctane sulphonic acid (PFOS) have received 84 
most attention in studies of humans and the environment. Increasing concern for their persistency 85 
and bioaccumulative properties has led to voluntary and regulatory efforts restricting their use, 86 
including: i) phasing out PFOS and related compounds while providing shorter chain PFSAs as 87 
replacements during 2000-2002 by 3M, the major producer (US EPA, 2002); ii) inclusion of 88 
PFOS in the Stockholm Convention in 2009 (Stockholm Convention); and iii), initiation of a 89 
PFOA stewardship program to phase out PFOA and longer chain PFCAs by 2015 (US EPA, 90 
2006). As a consequence of these actions, the global production of PFOS and related chemicals 91 
decreased drastically after the peak between 1990 and 2000 (Paul et al., 2009), although 92 
production of PFOS has continued in China (Zhang et al., 2012) and it is likely that production of 93 
longer chain PFASs continued for some years after 2002 (Armitage et al., 2009). 94 
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Overall, biomonitoring of PFASs in human serum has demonstrated decreasing concentrations of 95 
PFOS and PFOA since the early 2000s, whereas trends for other PFASs have been variable 96 
(Calafat et al., 2007a; Glynn et al., 2012; Harada et al., 2004; Jin et al., 2007; Kannan et al., 2004; 97 
Kato et al., 2011; Olsen et al., 2005; Olsen et al., 2012; Schröter-Kermani et al., 2012; Toms et 98 
al., 2009; Wang et al., 2011; Yeung et al., 2013a, 2013b). A cross-sectional study of pooled sera 99 
from 40-50 year old men in Norway during 1976 to 2007 reported that many PFASs increased 100 
during the study period and that PFOS, PFOA and perfluoroheptane sulphonic acid (PFHpS) 101 
started declining around year 2000 (Haug et al., 2009). The observed time trends of PFOS and 102 
PFOA in human serum, to a large extent, mirror the changes in global production. However, the 103 
reasons for differing time trends for different PFAS homologues and between different studies 104 
are not well understood. Furthermore, the decline in human concentrations of PFOA and PFOS 105 
after the phase-out initiated in year 2000 was observed after a short time lag considering its 106 
relatively long human elimination half-life (Olsen et al., 2007) and the absence of consistent 107 
decreasing trends in wildlife for the same time period (Butt et al., 2010). Time trends in human 108 
biomonitoring primarily reflect a combination of the temporal changes in exposure (intensity, 109 
duration and intake rates), and elimination kinetics (Quinn and Wania, 2012; Ritter et al., 2009). 110 
With respect to exposure pathways, the body burden of PFASs is greatly influenced by dietary 111 
intake, although drinking water, inhalation of indoor air, ingestion of house dust, and direct 112 
contact with consumer/commercial products may also contribute to a varying extent (Egeghy and 113 
Lorber, 2011; Fromme et al., 2009; Haug et al., 2011; Lorber and Egeghy, 2011;Vestergren and 114 
Cousins, 2009). Consequently, temporality in human exposure depends on the response time of 115 
the major source media to changes in PFAS production. Furthermore, exposure to PFASs in 116 
human populations in Arctic regions may have a different response time to changes in production 117 
due to the time-lag of long-range transport of PFASs by air and ocean currents (Butt et al., 2010). 118 
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Local or regional differences in contamination status together with life style differences and 119 
dietary habits may therefore result in different time trends between studies. 120 
In addition to different population exposures, observed human time trends may also be affected 121 
by the study design and demographic characteristics of the study group. Previous studies on 122 
legacy persistent organic pollutants (POPs) have demonstrated that an improved understanding of 123 
age, period and birth cohort effects is needed to correctly interpret time trends in biomonitoring 124 
studies (Nøst et al., 2013; Quinn and Wania, 2012; Ritter et al., 2009). Generally, no association 125 
(Calafat et al., 2007a, 2007b; Harada et al., 2007; Olsen et al., 2008; Yeung et al., 2006) and 126 
variable associations with age (Haug et al., 2009; Kato et al., 2011) have been reported for 127 
PFASs in cross-sectional studies. In one such study of pooled samples from Norwegian subjects, 128 
both positive and negative associations to age were reported, which varied between sampling 129 
years and the different PFASs (Haug et al., 2009).  130 
The present study describes changes in PFAS concentrations and compositional patterns in 131 
repeated serum samples during 1979-2007 and, to the best of our knowledge, this is the first to 132 
report repeated measurements of a number of PFASs in a non-occupationally exposed population. 133 
The rare longitudinal study design allowed for an assessment of periodic time trends during 134 
nearly 30 years in addition to the age and birth cohort effects (APC effects) in concentrations of 135 
selected PFASs.  136 
 137 
  138 
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2. Subjects and methodology 139 
2.1. Study population and subject selection 140 
Five repeated population surveys called the Tromsø study (summarized by Jacobsen et al., 2012) 141 
took place in the municipality of Tromsø, Northern Norway in 1979, 1986-1987 (hereafter 142 
referred to as 1986), 1994-1995 (1994), 2001 and 2007-2008 (2007). Adult men (n = 60) were 143 
randomly selected from 1438 males who had participated and donated blood in all five surveys of 144 
the Tromsø study. Of these, 53 had sufficient sample volumes in ≥3 sampling years and the 145 
present analyses comprised 254 serum samples (11 samples randomly distributed across sampling 146 
years were missing). Birth year information was extracted from questionnaires, while individual 147 
dietary information was inadequate. The range in birth years was 1925-1950, and the median 148 
ages at the first and last sampling were 43 and 71. Serum samples were stored at -70 °C until 149 
analysis. The study was approved by the Regional Committees for Medical Research Ethics. 150 
Participation was voluntary and participants gave informed consents.  151 
2.2. Analytical methodology 152 
Analyses were performed at the laboratories of NILU-Norwegian Institute for Air Research, 153 
Fram Centre, Tromsø, Norway. All serum samples were quantified for 10 target analytes and a 154 
subset of 43 samples were initially quantified for 21 analytes (see  Supplemental Material, Table 155 
S1). 156 
2.2.1. Extraction and clean up 157 
Serum samples were analysed using the internal-standard method and sonication-facilitated 158 
liquid-liquid extraction in methanol, activated charcoal clean up, and analysed by ultrahigh 159 
pressure liquid chromatography triple-quadrupole mass spectrometry (Thermo Fisher Scientific 160 
Inc, Waltham, MA, USA).  161 
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Extraction was performed as per Hanssen et al. (2013) with the following changes; i) 100 µl 162 
serum was extracted in a 1.5 ml eppendorf tube; ii) the internal standards (see Supplemental 163 
Material, Table S2 for list); iii) the volume methanol (750 µl) added; and iv) amount of branched 164 
perfluorodecanoic acid (br-PFDA) recovery standard (20 µl of 0.102 ng/µl) used.  165 
2.2.2. Instrumental analysis 166 
The analytical specifications are described in Hanssen et al. (2013). The quantification was 167 
conducted with the LC Quan software, version 2.6.0 (Thermo Fisher Scientific Inc, Waltham, 168 
MA, USA). Of the 21 PFASs included in the analyses, 10 were detected in >20% of samples in a 169 
subset of 20 samples and the remaining samples were quantified for these 10 PFASs. The linear 170 
and branched PFOS isomers were chromatographically separated (“branched PFOS” was 171 
identified as one or several peaks eluting earlier than the linear PFOS; see Supplemental Material, 172 
Fig. S1A). The mass-labeled internal standard for linear PFOS was also used for quantification of 173 
the branched isomers. Concentrations of branched PFOS presented were calculated as the mean 174 
concentrations of two transitions in the analysis (m/z 499-80 and 499-99), since response factors 175 
have been reported to differ between transitions of different isomers of PFOS (Berger et al., 176 
2011). Data presented as “PFOS” represent the sum of the linear and the coeluted peaks of 177 
branched isomers. Chromatographically separated branched and linear isomers could also be 178 
observed for perfluorooctane sulfonamide (FOSA) (see Supplemental Material, Fig. S1B); 179 
however, due to high variation (<80%) between isomers in parallel injections in some samples, 180 
the presented concentrations of FOSA represent the sum of isomers. For other PFASs, only the 181 






2.3. Quality assurance and sample integrity  186 
2.3.1. Quality control in PFAS analyses  187 
Blanks (n = 9) and standard reference materials (SRMs) [SRM® 1958 (n = 9) and 1957 (n = 9), 188 
both from the National Institute of Standards and Technology, Gaithersburg, MD, USA] were 189 
processed along with samples. The results for the SRM analyses were within +/-20% of reference 190 
values, except for perfluoroheptanoic acid (PFHpA), PFDA, PFUnDA for which the mean 191 
quantified concentrations were -30, -50 and -60% of reference values, respectively. The 192 
laboratory routinely participates in the Arctic Monitoring and Assessment Programme Ring Test 193 
for Persistent Organic Pollutants in Human Serum, and has performed within +/-20% of assigned 194 
values, which is considered excellent performance. [Ring test results are available from the 195 
Institut national de santé publique du Québec (2013).] 196 
All concentrations presented were within the calibration curve and the linear range of the 197 
instrument. For each compound in the mass spectrometry analyses, a second isotopic mass 198 
transition served to confirm compound specificity. The limits of detections (LODs) were set to 199 
three times the mean concentrations determined in blank samples (Table A.1 in the Appendix). 200 
Mean recoveries (range) of internal standards were 108% (69-145), 101% (67-132), 103% (66-201 
147), 108% (69-159), and 85% (42-142) for the 1979, 1986, 1994, 2001, 2007 samples, 202 
respectively. The recoveries in one sample preparation batch of 2007 samples were low (53% of 203 
2007 samples), although there was no association between recoveries and concentrations (data 204 
not presented). 205 
2.3.2. Estimation of desiccation 206 
To correct for spuriously elevated PFAS concentrations caused by evaporation during long-term 207 
storage, serum sodium (Na+) was measured and used to adjust plasma volumes as described in 208 
Nøst et al. (2013).  209 
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2.4. Data treatment and statistical methods 210 
Statistical analyses were executed using the software R, ver. 3.0.0 , and a statistical significance 211 
threshold of p < 0.05 was used. The statistical analyses included 254 samples (N = 53, 52, 48, 49 212 
and 52 at the five time points). All PFAS concentrations were log-normally distributed (Shapiro-213 
Wilk tests) and therefore loge-transformed in the statistical analyses.  214 
Summary statistics for compounds with detection frequencies >80% were calculated by 215 
conventional methods, whereas those occurring less frequently (20% - 80%) were computed for 216 
each sampling year using the Kaplan-Meier method employing the NADA package for R 217 
according to Helsel (2005). 218 
Spearman`s ρ values were calculated for correlations. Wilcoxon signed rank test was used to 219 
assess differences in PFAS concentrations between different sampling years, and Kruskal-Wallis 220 
rank sum test between birth year quartiles in each sampling year. The non-parametric Friedman`s 221 
test of repeated measurements was employed for differences across all sampling years. 222 
APC effects were assessed with age and birth cohort variables as quartiles. Mixed effect models 223 
(lme4 package for R) that allowed for subject-specific random variation, were used to assess 224 
periodic changes and potential age- and birth cohort-specific effects in concentrations of PFASs. 225 
The analyses were restricted to the fully detected PFOA, PFUnDA and PFOS to obtain the 226 
appropriate APC evaluation and model estimates. All models included a subject-specific random 227 
term and a random slope for sampling year, and the best fitted model was chosen based on 228 
Akaike`s Information Criterion (AIC) values (for details, see Nøst et al., 2013). Furthermore, 229 





3. Results 233 
3.1. Changes in PFAS concentrations during 1979-2007 234 
Serum concentrations and detection frequencies of 10 PFASs are presented in Table A.1 of the 235 
Appendix. Concentrations of PFOA, PFNA, PFDA, PFUnDA, PFHxS, PFHpS, PFOS and FOSA 236 
in each sampling year are depicted in Fig. 1, and temporal changes between consecutive sampling 237 




Table 1: Change in median concentrations (ng/ml) of the most abundant PFASs analysed in 242 
serum samples of men (N = 53, 52, 48, 49 and 52 in 1979, 1986, 1994, 2001 and 2007, 243 
respectively) in Northern Norway. Significant differences between years are indicated in Fig. 1. 244 
  1979-1986 1986-1994 1994-2001 2001-2007 
Compound Change in ng/ml  % Change in ng/ml  % Change in ng/ml  % Change in ng/ml  % 
PFOA 1.46 170 1.79 72 -0.23 -6 -0.99 -23 
PFNA 0.44 500 0.20 37 0.30 38 0.45 41 
PFDA 0.18 250 0.25 100 0.17 37 0.11 18 
PFUnDA 0.74 850 -0.05 -6 0.26 32 0.09 8 
PFHxS 0.54 260 0.61 85 0.41 27 -0.12 -6 
PFHpS 0.14 62 0.11 23 0.19 32 -0.10 -13 
PFOS 14.70 170 11.34 49 9.17 25 -9.39 -22 
FOSA 0.63 210 -0.05 -6 -0.11 -10 -0.59 -60 
  245 
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Fig. 1: Concentrations (ng/ml wet weight) of the most abundant PFASs analysed in repeated 246 
serum samples of men from Northern Norway (N =53, 52, 48, 49 and 52 in 1979, 1986, 1994, 247 
2001 and 2007, respectively). The asterisks denote significant differences in consecutive 248 
sampling years (p<0.001, Wilcoxon signed rank test). The boxplots for FOSA are censored box 249 
plots with the horizontal line indicating the LOD. One outlier for FOSA (13 ng/ml) in 2001 is not 250 
shown. 251 
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All quantified PFASs except perfluorohexanoic acid (PFHxA) increased from the initial 253 
concentrations in 1979. The median concentrations of PFOA and PFOS increased five-fold from 254 
1979 to 2001 and decreased by 26% and 23%, respectively, from 2001 to 2007. Concentrations 255 
peaked in 1994 for PFHpA; in 1994 and 2001 for PFOA; and in 2001 for PFHxS and PFOS (not 256 
significant for PFHxS). Concentrations of FOSA reached a plateau from 1986 to 2001 and 257 
decreased to 2007. Continuously increasing concentrations across the study period were observed 258 
for PFNA, PFDA, PFUnDA, although not statistically significant between all years; and the rate 259 
of increase varied between the different homologues and years. Individual trend curves are 260 
presented for PFOS and PFOA in Fig. 2 and Supplemental Material, Fig. S2, respectively; they 261 
display generally consistent trends among individuals with the largest concentration ranges in 262 
2001 and 2007.  263 
Perfluorobutanoic acid (PFBA) and perfluoropentanoic acid (PFPeA) were detected in the 264 
samples, but the quantified concentrations are not presented due to the lack of a confirmatory ion 265 
transition in the instrumental analysis. However, reanalysis of three samples from different years 266 
by Acquity UPLC -MS-MS (ES-, MRM, Waters Tandem Quadrupol Detector) and HR-MS (ES-, 267 
Full Scan, LTQ Orbitrap, Thermo Scientific) qualitatively confirmed their presence.  268 
  269 
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Fig. 2: Individual trend lines for PFOS concentrations in repeated measurements in 1979, 1986, 270 
1994, 2001 and 2007 in serum samples of men from Northern Norway. Trend lines are displayed 271 
according to birth year quartiles.  272 
 273 



























































































































3.2.PFAS correlations between subsequent measurements 275 
Correlations between two subsequent measurements of a PFAS varied during the sample period 276 
(Table 2), and were the strongest between the measurements in 2001 and 2007 for most PFASs. 277 
However, those for PFOS and PFOA were robust (Spearman`s ρ >0.6) between all subsequent 278 
measurements. 279 
 280 
Table 2: Spearman`s ρ for significant correlations (p<0.05) between subsequent measurements.  281 






PFOA 0.65 0.66 0.60 0.75 
PFNA 0.44 0.65 0.63 0.60 
PFDA 0.50 0.42 0.59 0.71 
PFUnDA 0.35 0.56 0.61 0.79 
PFHxS 0.59 0.63 0.46 0.81 
PFHpS 0.43 0.48 0.36 0.66 
PFOS 0.84 0.65 0.62 0.81 




3.3.Compositional patterns and correlations between PFASs 285 
The most abundant PFASs in all years were PFOS (78-82% of summed median PFAS 286 
concentrations) >PFOA (7-9%) >PFHxS (2-5%) >PFUnDA (1-3%); compositional patterns of 287 
PFASs for each sampling year are indicated in Fig. 3. Median PFOS concentrations were 9-10 288 
times higher than those of PFOA in all sampling years. Decreasing ratios across sampling years 289 
were observed for other pairs: 9, 5, 5, 4, 2 for PFOA/PFNA, 12, 10, 9, 7, 4 for PFOA/PFDA and 290 
9, 3, 5, 4, and 3 for PFOA/PFUnDA in 1979, 1986, 1994, 2001 and 2007, respectively.   291 
16 
 
Fig. 3: Relative contributions of the different PFASs to their sum (in %) are presented for five 292 
repeated serum measurements in men from Northern Norway (N = 53, 52, 48, 49 and 52 in 1979, 293 
1986, 1994, 2001 and 2007, respectively).  294 
 295 
 296 
The median percentages of linear isomers to summed PFOS concentrations were quite stable 297 
(68% - 72%; Table A.1 in the Appendix), but the percentages of linear PFOS in 1994 and 2001 298 
were significantly different (Wilcoxon paired rank sum, p<0.0001). Some individual variation in 299 
temporal trends for percentage of linear isomer was observed (Supplemental Material, Fig. S3). 300 
The correlations between PFASs in each sampling year are presented in Supplemental Material, 301 
Table S3. Those for PFOS and PFOA were quite stable (Spearman`s ρ: 0.3-0.4) during the study 302 
period, while they generally increased for PFNA, PFDA and PFUnDA (especially between 303 
PFDA and PFUnDA, with Spearman`s ρ= 0.4, 0.6, 0.7, 0.8, 0.9 in 1979, 1986, 1994, 2001 and 304 
2007, respectively). Furthermore PFNA and PFOS correlated well (Spearman`s ρ >0.6) 305 
throughout the period, and the associations of PFDA and PFUnDA with PFOS strengthened. 306 
















However, those between PFHxS and PFOS decreased slightly and the correlation between FOSA 307 
and PFOS increased from 1979 to 1994 and declined thereafter.  308 
 309 
3.4. Age-period-cohort effects in concentrations of PFOA, PFUnDA and PFOS 310 
Estimates from mixed effect models for PFOA, PFUnDA and PFOS are presented in 311 
Supplemental Material, Tables S4-6. The best fitted model for PFOS and PFOA included only 312 
sampling year as a fixed predictor, whereas for PFUnDA it also included birth cohort as a fixed 313 
factor and age as a random term. Selected graphical displays of age-period-cohort effects in Fig. 314 
4 present longitudinal and cross-sectional organizations of PFOA, PFUnDA and PFOS 315 
concentrations (those for PFHpA, PFNA, PFDA and PFHxS are presented in Supplemental 316 
Material, Fig. S4). The change in concentrations of PFOS from 2001 to 2007 was not 317 
significantly different across age quartiles (Kruskal-Wallis rank sum test, p>0.05). 318 
 319 
  320 
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Fig. 4: APC plots: Longitudinal (age and period effects are confounded) and cross-sectional (age 321 
and birth year effects are confounded) organization of PFOS and PFOA concentrations (medians 322 
for each quartile in each sampling year, in ng/ml wet weight). The asterisk indicates significant 323 
birth cohort differences (Kruskal-Wallis rank sum test, p<0.05).  324 
  325 
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4. Discussion 326 
4.1. Time trends in PFAS concentrations   327 
The observed longitudinal trends of PFASs in a population experiencing background exposure 328 
during a thirty year period covering the years of most intense production of PFOS-related 329 
compounds provide new insight. Overall, time trends for PFOA, PFOS and FOSA (Fig. 1) are in 330 
harmony with the global production history of long-chain PFASs (Paul et al., 2009; Prevedouros 331 
et al., 2006). The relatively rapid response in serum concentrations of PFOA and PFOS observed 332 
in this and other studies following reduced production during 2000-2002 is somewhat remarkable 333 
considering their long human half-lives (Olsen et al., 2007) and the absence of concurrent and 334 
distinct decreases in PFOA and PFOS concentrations in wild-life studies (Butt et al., 2010; 335 
Holmström et al., 2010). Although a levelling off or slight decrease in PFOS concentrations was 336 
observed in wild-life in Northern Norway during this period (Ahrens et al., 2011; Verreault et al., 337 
2007), the observed declines in human sera in this study cannot be explained by concurrent 338 
decreases in PFAS exposures through human food-chains. Further, the stable ratio and correlation 339 
between PFOS and PFOA during 1979-2007 suggest that their exposure pathways have changed 340 
little or done so concomitantly during this period. One hypothesis, which has been proposed to 341 
explain the concurrent decrease in serum concentrations of PFOA and PFOS in cross-sectional 342 
studies in other countries, states that consumer products made a significant contribution to the 343 
total exposure (direct or through degradation of precursors) to these compounds prior to year 344 
2000 (D’eon and Mabury, 2011; Jackson and Mabury, 2012; Olsen et al., 2008; Vestergren and 345 
Cousins, 2009). As their production ceased during 2000-2002 human serum concentrations of 346 
PFOA and PFOS might be expected to converge as diet-linked environmental pathways would 347 
become increasingly important in a post ban situation (Vestergren and Cousins, 2009). 348 
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Indications of an earlier peak in PFOA concentrations relative to those of PFOS in some 349 
individuals (Fig. 2 and S2) likely reflect the somewhat longer human elimination half-life of 350 
PFOS compared to PFOA (4.6 and 3.4 years, respectively, estimated median in fluorochemical 351 
production workers by Olsen et al. (2007)). Concentrations of PFHxS did not display a 352 
significant decrease from 2001 to 2007 (Fig. 1) despite that production of this compound was 353 
phased out at the same time as PFOS (Kannan et al., 2004). The diverging time trends of PFHxS 354 
and PFOS could be due to the longer elimination half-life of PFHxS (7.1 years; Olsen et al., 355 
2007) relative to PFOS and a relatively higher exposure of PFHxS through the food-chain 356 
exposure pathway suggested throughout the study period compared to PFOS. Concentrations of 357 
FOSA were quite stable from 1986 to 2001 and decreased to 2007. This compound has been 358 
shown to be a precursor of PFOS (Xu et al., 2004) as well as a metabolite of other precursor 359 
compounds (Benskin et al., 2007). The time trend of FOSA as a precursor compound is as such 360 
interesting, and the decrease from 2001 to 2007 could contribute to the observed decline in PFOS 361 
concentrations. Furthermore, the FOSA decline could also reflect the decline of other precursor 362 
compounds, which is in line with such trends reported for two German cities (Yeung et al., 363 
2013a,b).  364 
PFNA, PFDA and PFUnDA concentrations increased from 1979 to 2007 (not significantly so for 365 
every sampling year) which could be due to their continued production after 2001 (Armitage et 366 
al., 2009) along with longer elimination half-lives and bioaccumulation ability compared to 367 
shorter-chain PFCAs (Conder et al., 2008; Zhang et al., 2013). As opposed to for PFOA and 368 
PFOS, time trends of these compounds in humans are more in accordance with those observed in 369 
wild-life biomonitoring (Ahrens et al., 2011; Butt et al., 2010; Holmström et al., 2010; Verreault 370 
et al., 2007). Inter-correlations between PFNA, PFDA and PFUnDA as well as their strengthened 371 
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correlations to PFOS over the same period suggest a gradual co-exposure through environmental 372 
background concentrations rather than consumer products (Vestergren and Cousins, 2009). 373 
Although human exposure pathways of C>8 PFCAs are not well understood, recent dietary intake 374 
studies (e.g. Vestergren et al., 2013) and biomonitoring studies (e.g. Brantsæter et al., 2013) 375 
demonstrate that human concentrations of these compounds are currently linked to the diet. The 376 
increasing time trends signify the concern towards human body burdens of longer-chain PFCAs. 377 
Cross-sectional time trend studies involve testing different subjects at each sampling point, while 378 
our longitudinal study follow the same aging individuals. Comparing our PFAS time trends to 379 
those in pooled sera from Norwegian men (aged 40-50 at the time of each collection) during 380 
1977-2006 (Haug et al., 2009) revealed interesting similarities and differences. The 381 
concentrations and temporal changes of PFOA observed were comparable between the studies 382 
and demonstrate a uniform exposure to PFOA during these years (Supplemental Material, Fig. 383 
S5). Furthermore, concentrations of PFOS in 1979 were similar to those in Haug et al., but the 384 
subsequent incline to later years was steeper in our study and the decline from 2001 was less 385 
pronounced (-23% during 2001-2007 in this study, and -55% during 2001-2006 in Haug et al. 386 
(2009)). PFNA, PFDA and PFUnDA increased more during the study period in men from 387 
Northern Norway compared to those in Haug et al. (Supplemental Material, Fig. S5). The 388 
observed differences in time trends could partly be explained by the enhanced and prolonged 389 
exposure to these compounds in the Northern Norwegian men, possibly related to their expected 390 
higher fish consumption (Alexander et al., 2006; Johansson and Solvoll, 1999; Nøst et al., 2013). 391 
However, the different study designs and resulting age group differences (intraindividual versus 392 
interindividual age differences in longitudinal and cross-sectional studies, respectively), could 393 
also contribute to the discrepancies. It may also be noted that environmental concentrations of 394 
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PFOS in northern latitudes are expected to respond more slowly to changes in their production 395 
and use due to the slow transport of PFOS with ocean currents (Armitage et al., 2009). 396 
The decline in PFOS from 2001 to 2007 was also less pronounced in the Northern Norwegian 397 
men when compared to cross-sectional studies in Germany and U.S.A. although time trends for 398 
PFOA, PFNA and PFHxS in 2001 and 2007 were comparable (Supplemental Material, Fig. S5) 399 
(Kato et al., 2011; Olsen et al., 2012; Schröter-Kermani et al., 2012). Further, concentrations 400 
were generally higher for PFOS, slightly lower for PFOA, and comparable for PFNA and PFHxS 401 
in the Northern Norwegian men. Again this likely reflects the difference in study designs and 402 
characteristics of the exposure experienced by the different populations. 403 
4.2. Changing correlations between subsequent measurements  404 
Correlations between subsequent measurements varied across the sampling period but became 405 
stronger in 2001-2007 relative to the earlier years. Notably, correlations for PFUnDA became 406 
stronger throughout. The varying correlations could reflect changing intensities and pathways of 407 
human PFAS exposures during 1979-2007. It is likely that in the earliest years, human exposure 408 
pathways were various and intensities increased (Paul et al., 2009; Prevedouros et al., 2006). In 409 
accordance with this, the widest concentration ranges of PFOA and PFOS were observed in the 410 
years of highest concentrations (1994 and 2001; Fig. 2 and S2), and likely reflect large individual 411 
variation in exposures when intensities peaked. After 2001, exposure intensities decreased and 412 
contribution of the human food chain likely increased. Indeed, diet is suspected to be the major 413 
current exposure route of PFASs for humans (Egeghy and Lorber, 2011; Fromme et al., 2009; 414 




4.3.Time trends in relative compositions  417 
Relative production and use of the different PFASs, environmental persistence, human half-lives, 418 
precursor chemistry and exposure pathways must all be kept in mind when considering human 419 
compositional PFAS patterns over time. PFOS was most abundant in all years, but PFOA and 420 
PFHxS also contributed substantially to the PFAS burdens. The relative contribution to the sum 421 
of PFASs by PFOA and PFOS were stable during the study (Fig. 3), whereas those for PFNA, 422 
PFDA and PFUnDA increased. Higher bioaccumulation potentials have been proposed for longer 423 
chain PFCAs (Conder et al., 2008), and could explain the prolonged exposure to these 424 
compounds from the environment. The PFOA/PFNA ratio decreased from 1979 to 2007, and the 425 
relative decrease in PFOA could reflect the declining production and use of PFOA and the 426 
increasing influence of food-chain related exposure as PFNA>PFOA in wildlife (Vestergren and 427 
Cousins, 2009; Butt et al., 2010). This is also likely valid for the similar trends in PFOA/PFDA 428 
and PFOA/PFUnDA ratios. The relative concentration of FOSA decreased during the study 429 
period, but the proportions reported are underestimated in this study as 80-90% of FOSA is 430 
associated with the cell fraction discarded from plasma/serum (Kärrman et al., 2006; Hanssen et 431 
al., 2013).  432 
No consistent trend was observed among subjects for the relative percentages of linear and 433 
branched isomers of PFOS over time (Fig. S3). However, it should be noted that there were 434 
individual variations in the percentage of branched PFOS. Enriched profiles of branched PFOS 435 
(>30% branched) has been suggested as a biomarker of exposure to PFOS precursors (Martin et 436 
al., 2010). In line with Martin et al. (2010), the relative constant contribution from branched 437 
PFOS of around 30% indicate direct exposure to PFOS, rather than exposure to PFOS precursors 438 
for the studied population. Differences in the quantification procedure (Berger et al., 2011; 439 
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Riddell et al., 2009) and individual differences in PFOS isomer profiles should therefore be 440 
further investigated to clarify the relative importance of PFOS precursors for human exposure. 441 
Qualitative confirmation of presence of PFBA and PFPeA in three random samples (from 442 
different years) indicates that these compounds should be investigated in future monitoring of 443 
PFASs. Fluorotelomer sulphonic acids (FTSAs; 4:2, 6:2 and 8:2), perfluorobutane sulphonic acid 444 
(PFBS), perfluorodecane sulphonic acid (PFDcS) or C12-14 and C16 PFCAs were not detected 445 
in any sampling year and indicate that the past and recent exposure to these compounds has been 446 
low or their elimination rate high relative to the exposure. 447 
 448 
4.4. Age-period-cohort effects for PFOA, PFUnDA and PFOS 449 
Calendar year of sampling was the strongest predictor of PFAS concentrations and the calendar 450 
year trends reveal that human concentrations reflect overall historic trends in production and use 451 
of PFASs (see Section 4.1). Although time trends differed between PFASs, the influence of 452 
calendar year was evident for most compounds.  453 
Including age or birth cohort predictors in addition to sampling year in mixed models for PFOA 454 
and PFOS did not improve model fits and indicates that these variables were of less importance 455 
compared to sampling year. The persons in the current study were all born before the onset of 456 
large-scale PFAS production and the exposure (duration and intensity) to all persons was 457 
expected to be similar at the times of sampling. Indeed, concentrations were not significantly 458 
different between age/birth cohort quartiles other than for PFOA in 1994, with the youngest 459 
quartiles having the highest concentrations compared to the older quartiles. Furthermore, when 460 
the results were organised cross-sectionally, age-associations were variable between years and 461 
indicate that these associations must be understood in relation to historic production and use (Fig. 462 
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4 and S4). Variable associations of PFASs to age between sampling years were also reported in 463 
the pooled, cross-sectional data from Norway (Haug et al., 2009). Compared to PFOA and PFOS, 464 
the mixed model fit improved for PFUnDA when including birth year quartiles as fixed factors 465 
and age as a random effect. This suggests that experienced exposure or elimination rates could 466 
differ between birth year quartiles.  467 
Associations between POP concentrations and age in a population are not only affected by 468 
historic production and use relative to the sampling time, age structure of the study population, 469 
and compound persistence (Quinn and Wania, 2012; Ritter et al., 2009), but also by exposure 470 
pathways, and age-dependent PFAS intake rates related to e.g. dietary habits (Haug et al., 2010) 471 
relative to elimination rates. In post-ban exposure scenarios, the so-called legacy POPs have often 472 
been reported to increase with age in cross-sectional studies. This association likely reflects birth-473 
cohort differences in duration and intensity of exposure to these compounds (Nøst et al., 2013; 474 
Quinn and Wania, 2012; Ritter et al., 2009). However, reports of correlations of PFASs to age are 475 
not consistent in cross-sectional studies (Calafat et al., 2007a, 2007b; Harada et al., 2007; Haug et 476 
al., 2009; Kato et al., 2011; Olsen et al., 2008; Yeung et al., 2006), and may be due to similar 477 
exposures for all age groups/birth cohorts due to recent or ongoing production and use. Age-478 
differentiated intake rates (e.g. Tittlemier et al., 2007) or toxicokinetic properties could influence 479 
individual trends of PFASs over time, although differences in internal kinetics appear not to be 480 
strong in the general population (Harada et al., 2005). Furthermore, the present results suggest 481 
that the coarse features of temporal trends relate to changes in production and use. It is 482 
anticipated that diet-linked environmental exposures and time passed since peak production will 483 




4.5. Study limitations and future perspectives 486 
The longitudinal serum data for PFASs in the present study allowed an improved understanding 487 
for how human concentrations of these compounds have changed in relation to production and 488 
use patterns. Further studies of longitudinal evaluation of additional precursor compounds such as 489 
listed by Martin et al. (2010), Calafat et al. (2007a), and Yeung et al. (2013a,b), and isomer-490 
specific analyses could have offered additional knowledge of the relative importance of PFOS 491 
precursors in PFAS time trends and pathway tracking. However, the analytical methodology 492 
employed in this study did not allow for that.  493 
FOSA concentrations were presented as a sum of isomers due to high analytical variation 494 
between the branched and linear peaks in parallel sample injections. It should be mentioned that 495 
SRM results indicated that concentrations of PFHpA, PFDA and PFUnDA were underestimated 496 
(see Section 2.3.1.). Thus the reported concentrations of these analytes might constitute a low 497 
estimate although the time trends would not be affected by this. The limitations regarding 498 
statistical approaches to assess APC effects in POP concentrations in the current study group are 499 
described in Nøst et al. (2013).   500 
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5. Conclusion 501 
This study describes past and current exposure to PFASs in the same men in a coastal population 502 
experiencing background exposure. The nearly 30-year time trends of PFAS concentrations in the 503 
repeated measurements from men in Northern Norway suggested unique time trends for the 504 
different PFASs quantified. We have demonstrated that human concentrations of PFASs have 505 
followed overall trends in production and use although compound differences in global transport 506 
mechanisms, bioaccumulation potentials and a varying extent of consumer exposures influence 507 
the observed trends. PFOA and PFOS concentrations decreased after 2001, as opposed to the 508 
increasing trends of PFNA, PFDA and PFUnDA throughout the study period.  509 
The assessments of age-period-birth cohort effects demonstrated that calendar time was the 510 
dominating influence on PFAS concentrations, and associations to age/birth cohorts were 511 
variable between sampling years and not significant.  512 
 513 
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APPENDIX  711 
Table A.1: Concentrations (ng/ml) of PFASsa analysed in repeated serum samples from men in Northern Norway. 712 
 




























PFHxA  -   
(<LOD-0.1) 
0.1 32  -   
(<LOD-0.2) 
0.1 42  -   
(<LOD-0.2) 
0.1 27  -  
 (<LOD-0.1) 
0.1 25  -  
 (<LOD-0.2) 
0.1 35 0.05 
PFHpA 0  
(<LOD-0.1) 
0 60 0  
(<LOD-0.1) 
0 75 0.1  
(<LOD-0.7) 
0.1 95 0.1  
(<LOD-0.7) 
0.1 77 0.1  
(<LOD-0.2) 
0.1 87 0.03 
PFOA 0.9  
(0.4-2.5) 
1 100 2.5  
(1.4-4.5) 
2.5 100 3.9  
(2-9.6) 
4.6 100 4.2  
(1.8-9.9) 
4.4 100 3.1  
(1.3-6.8) 
3.2 100 0.13 
PFNA 0.1  
(<LOD-0.2) 
0.1 81 0.5  
(0.2-1.3) 
0.6 100 0.8  
(0.2-1.6) 
0.8 100 1.1  
(0.5-1.9) 
1.2 100 1.5  
(0.7-3.4) 
1.6 100 0.05 
PFDA 0.1  
(<LOD-0.2) 
0.1 91 0.3  
(0.1-0.7) 
0.3 100 0.5  
(0.1-1.1) 
0.5 100 0.7  
(0.2-1.7) 
0.7 100 0.8  
(0.2-1.8) 
0.8 100 0.03 
PFUnDA 0.1  
(<LOD-0.7) 
0.1 87 0.8  
(0.3-3) 
0.9 100 0.8  
(0.1-2.4) 
0.9 100 1.1  
(0.4-4.5) 
1.3 100 1.3  
(0.1-3.9) 
1.4 100 0.04 
PFHxS 0.2  
(0.1-3) 
0.3 100 0.7  
(0.4-5.3) 
1 100 1.5  
(0.3-4.8) 
1.5 100 2  
(0.6-12) 
2.6 100 1.9  
(0.6-12) 
2.3 100 0.03 
PFHpS 0.2 
(<LOD-1.9) 
0.3 92 0.5  
(<LOD-1.9) 
0.5 96 0.6  
(0.2-2) 
0.7 100 0.8  
(<LOD-1.7) 
0.8 98 0.7  
(0.2-1.5) 
0.7 100 0.10 
Branched PFOS 2.7  
(1.1-20) 
3 100 7.2 
(3.2-27) 
7.8 100 11 
(2.8-21) 
11 100 12  
(<LOD-25) 
13 98 8.7  
(3.1-18) 
9.4 100 0.08 
Linear PFOS 5.7  
(2.4-18) 
6.3 100 16  
(7.2-43) 
17 100 25  
(9.2-52) 
25 100 30  
(12-70) 
33 100 23  
(6.5-47) 
24 100 0.07 
PFOS 8.6  
(3.7-38) 
9.3 100 23  
(10-61) 
25 100 37  
(13-73) 
37 100 43 
 (20-90) 
46 100 33  
(11-65) 
33 100 0.15 
FOSA 0.3 
(0-1.1) 
0.4 100 0.9  
(0.3-4.2) 
1.2 100 1  
(0.2-6.8) 
1.2 100 1  
(0.1-13) 
1.4 100 0.2  
(0-1.3) 
0.3 100 0.02 
% linear PFOS 69  
(48-79) 
69  69  
(56-77) 
69  68  
(57-79) 
68  71  
(60-82) 




aFor compound abbreviations, see Table S1. Censored summary statistics are presented for compounds with detection frequencies less 713 
than 80%: PFHxA and PFHpA. Results are not presented for compounds detected in <20% of samples in a subset of 20 samples: 714 
PFBA, PFPeA, PFDoDA, PFTrDA, PFTeDA, PFHxDA, PFBS, PFDcS, and FTSAs (4:2, 6:2 and 8:2). 715 
b% > LOD = Percentage of samples in which analyte was detected.  716 
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Table S1: Abbreviations of chemical names for the PFASs analysed  748 
Abbreviation Compound 
4:2 FTSA 4:2 fluorotelomer sulphonic acid 
6:2 FTSA 6:2 fluorotelomer sulphonic acid 
8:2 FTSA 8:2 fluorotelomer sulphonic acid 
PFBA Perfluorobutanoic acid 
PFPeA Perfluoropentanoic acid 
PFHxA Perfluorohexanoic acid 
PFHpA Perfluoroheptanoic acid 
PFOA Perfluorooctanoic acid 
PFNA Perfluorononanoic acid 
PFDA Perfluorodecanoic acid 
PFUnDA Perfluoroundecanoic acid 
PFDoDA Perfluorododecanoic acid 
PFTrDA Perfluorotridecanoic acid 
PFTeDA Perfluorotetradecanoic acid 
PFHxDA Perfluorohexadecanoic acid 
PFBS Perfluorobutane sulphonic acid 
PFHxS Perfluorohexane sulphonic acid 
PFHpS Perfluoroheptane sulphonic acid 
PFOS  Perfluorooctane sulphonic acid 
PFDcS Perfluorodecane sulphonic acid 
FOSA Perfluorooctane sulfonamide 
 749 
 750 
Table S2: Internal standard mixture 751 
Labeled compound Concentration 
13C4 PFBA 0.1 ng/µl 
13C5 PFPeA 0.1 ng/µl 
13C5 PFHxA 0.1 ng/µl 
13C4 PFHpA 0.1 ng/µl 
13C4 PFOA 0.1 ng/µl 
13C5 PFNA 0.1 ng/µl 
13C6 PFDA 0.1 ng/µl 
13C7 PFUnDA 0.1 ng/µl 
13C2 PFDoA 0.1 ng/µl 
13C3 PFHxS 0.0946 ng/µl 
13C4 PFOS 0.0956 ng/µl 




Fig. S1: Examples of chromatograms displaying branched and linear isomers of PFOS (A) and 753 
FOSA (B) in serum samples. The branched isomers were identified as eluting earlier than the 754 
linear isomers. 755 
A)       B) 756 
 757 
  758 
PFC_120718_ZHN_133 - m/z= 80.00-80.00 RT: 6.39 - 7.20 NL: 1.94E3
F: - c ESI SRM ms2  499.002 [ 79.999-80.001, 98.999-99.001]



































6.56 6.60 6.96 7.087.016.43 7.13 7.186.52
PFC_120718_ZHN_136 - m/z= 78.00-78.00 RT: 7.44 - 7.82 NL: 2.24E2
F: - c ESI SRM ms2  498.027 [ 77.999-78.001, 498.026-498.028]






































Fig. S2: Individual trend lines for PFOA concentrations in repeated measurements in 1979, 1986, 759 
1994, 2001 and 2007 in serum samples of men from Northern Norway. Results are separated into 760 













































































Fig. S3: Individual trend lines for percent of the linear PFOS isomer of summed PFOS 764 
concentrations in repeated measurements in 1979, 1986, 1994, 2001 and 2007 in serum samples 765 
of men from Northern Norway. Results are separated into birth year quartiles. 766 
767 



































































































































Table S3: Correlation coefficients (Spearman`s ρ) for associations between PFASs presented 769 
separately for the sampling years. Numbers in bold are significant at the level p<0.05. 770 
     1979 PFHpA PFHxS PFHpS PFOA PFNA PFDA PFUnDA PFOS 
PFHpA 
        PFHxS 0.12 
       PFHpS 0.12 0.23 
      PFOA 0.18 0.29 0.04 
     PFNA 0.12 0.29 -0.11 0.34 
    PFDA 0.15 -0.13 -0.16 -0.17 0.19 
   PFUnDA -0.13 0.06 -0.09 -0.05 0.32 0.38 
  PFOS 0.15 0.73 0.09 0.41 0.61 0.12 0.27 
 FOSA 0.09 0.13 -0.14 0.17 0.3 0.24 0.22 0.3 
              1986 PFHpA PFHxS PFHpS PFOA PFNA PFDA PFUnDA PFOS 
PFHpA 
        PFHxS 0.04 
       PFHpS 0.03 0.3 
      PFOA 0.15 0.31 0.31 
     PFNA -0.15 0.52 0.18 0.18 
    PFDA -0.02 0.31 0.16 -0.03 0.57 
   PFUnDA -0.05 0.31 -0.06 -0.12 0.59 0.62 
  PFOS -0.13 0.72 0.31 0.32 0.7 0.39 0.54 
 FOSA -0.03 0.2 0.16 0.26 0.35 0.12 0.25 0.47 
               1994 PFHpA PFHxS PFHpS PFOA PFNA PFDA PFUnDA PFOS 
PFHpA 
        PFHxS 0.01 
       PFHpS 0.06 0.32 
      PFOA 0.41 0.22 0.24 
     PFNA 0.09 0.65 0.22 0.38 
    PFDA 0.06 0.57 0.09 0.23 0.8 
   PFUnDA -0.08 0.55 0.06 -0.07 0.65 0.74 
  PFOS -0.12 0.68 0.36 0.31 0.63 0.61 0.64 
 FOSA 0.25 0.31 0.25 0.5 0.54 0.48 0.4 0.55 
              2001 PFHpA PFHxS PFHpS PFOA PFNA PFDA PFUnDA PFOS 
PFHpA 
        PFHxS 0.08 
       PFHpS 0.07 0.64 
      PFOA 0.49 0.48 0.47 
     PFNA 0.18 0.55 0.48 0.44 
    PFDA 0.21 0.29 0.25 0.25 0.71 
   PFUnDA 0.12 0.25 0.13 0.03 0.54 0.84 
  PFOS 0.1 0.66 0.62 0.32 0.67 0.62 0.62 
 FOSA 0.24 0.08 -0.04 0.09 0.3 0.26 0.37 0.29 
               2007 PFHpA PFHxS PFHpS PFOA PFNA PFDA PFUnDA PFOS 
PFHpA 
        PFHxS -0.02 
       PFHpS -0.07 0.53 
      PFOA 0.13 0.43 0.55 
     PFNA -0.18 0.41 0.39 0.44 
    PFDA -0.23 0.36 0.28 0.25 0.74 
   PFUnDA -0.22 0.26 0.06 -0.04 0.57 0.89 
  PFOS -0.23 0.61 0.5 0.35 0.68 0.77 0.72 
 FOSA 0.05 0.18 0.21 0.02 0.31 0.12 0.16 0.18 
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Table S4: Mixed effect model estimatesa (coefficients and 95% CI) of PFOA concentrations (ng/ml) in men from Northern Norway 771 
from 1979 to 2007 with age, calendar period and birth cohort as predictors.  772 
Predictors and 
coefficients 
  Model 1: Period 
only (fixed effects) 
Model 2: Period and 
age (fixed effects) 
Model 3: Period and age (fixed 
effects) plus birth cohort 
(random effects)b 
Model 4: Period and 
birth cohort (fixed 
effects) 
Model 5: Period and birth 
cohort (fixed effects) plus age 
(random effect)b 
Periodc 
           
1979 
 
Ref - Ref - Ref - Ref - Ref - 
1986 
 
1.5 (1,2.1) 1.4 (0.9,2.1) 1.7 (1.3,2.3) 1.3 (0.7,2.1) 1.3 (0.8,1.8) 
1994 
 
3.4 (2.4,4.7) 3.2 (2,4.8) 4.5 (3.4,5.9) 3.0 (1.9,4.6) 2.6 (1.7,3.8) 
2001 
 
3.1 (2.1,4.3) 2.9 (1.7,4.7) 4.5 (3.4,5.9) 2.8 (1.7,4.3) 2.6 (1.9,3.6) 
2007 
 
2.1 (1.4,3) 2.0 (1,3.4) 3.3 (2.3,4.7) 1.8 (1.1,3) 1.8 (1.1,2.6) 
Aged 

































Birth cohorte  




































0.1 (-0.2,0.7) 0.2 (-0.1,0.6) 
AICf   132   149   152   143   145   
aCoefficients are back-transformed from log-estimates of fixed effect variables. All models included a subject-specific random term 773 
and a random slope for sampling year. Age and birth cohort variables were divided into quartiles.  774 
bVariables were added to models as random terms to allow for random variation in individuals. 775 
cCoefficients express change for PFOA concentrations in ng/ml across sampling years with 1979 as reference. 776 
dCoefficients express change in PFOA concentrations in ng/ml across age quartiles with the youngest (29-47) as reference. 777 
eCoefficients express change in PFOA concentrations in ng/ml across birth cohort quartiles with the oldest (1925-1934) as reference. 778 
fAkaike’s information criterion. Lower numbers indicate better model fit when comparing models. 779 
 780 
  781 
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Table S5: Mixed effect model estimatesa (coefficients and 95% CI) of PFUnDA concentrations (ng/ml) in men from Northern Norway 782 
from 1979 to 2007 with age, calendar period and birth cohort as predictors.  783 
Predictors and 
coefficients 
  Model 1: Period 
only (fixed effects) 
Model 2: Period and 
age (fixed effects) 
Model 3: Period and age 
(fixed effects) plus birth 
cohort (random effects)b 
Model 4: Period and 
birth cohort (fixed 
effects) 
Model 5: Period and birth 
cohort (fixed effects) plus age 
(random effect)b 
Period 
           
1979 
 
Ref - Ref - Ref - Ref - Ref - 
1986 
 
0.74 (0.5,1.2) 0.68 (0.4,1.1) 0.65 (0.4,1) 0.89 (0.5,1.6) 0.94 (0.5,1.7) 
1994 
 
0.73 (0.4,1.2) 0.60 (0.3,1.1) 0.63 (0.4,1.1) 0.88 (0.5,1.6) 0.85 (0.5,1.5) 
2001 
 
1.04 (0.6,1.6) 0.80 (0.4,1.5) 0.82 (0.5,1.4) 1.26 (0.7,2.3) 1.33 (0.7,2.4) 
2007 
 
1.05 (0.6,1.7) 0.78 (0.4,1.6) 0.91 (0.5,1.7) 1.27 (0.6,2.4) 1.31 (0.7,2.4) 
Age 

































Birth cohort  




































-0.03 (-0.1,0) -0.04 (-0.1,0) 
AIC   364   375   393   370   352   
aCoefficients are back-transformed from log-estimates of fixed effect variables. All models included a subject-specific random term 784 
and a random slope for sampling year. Age and birth cohort variables were divided into quartiles.  785 
bVariables were added to models as random terms to allow for random variation in individuals. 786 
cCoefficients express change for PFUnDA concentrations in ng/ml across sampling years with 1979 as reference. 787 
dCoefficients express change in PFUnDA concentrations in ng/ml across age quartiles with the youngest (29-47) as reference. 788 
eCoefficients express change in PFUnDA concentrations in ng/ml across birth cohort quartiles with the oldest (1925-1934) as 789 
reference. 790 
fAkaike’s information criterion. Lower numbers indicate better model fit when comparing models.  791 
9 
 
Table S6: Mixed effect model estimatesa (coefficients and 95% CI) of PFOS concentrations (ng/ml) in men from Northern Norway 792 
from 1979 to 2007 with age, calendar period and birth cohort as predictors. 793 
Predictors and 
coefficients 
  Model 1: Period only 
(fixed effects) 
Model 2: Period and 
age (fixed effects) 
Model 3: Period and age 
(fixed effects) plus birth 
cohort (random effects)b 
Model 4: Period and 
birth cohort (fixed 
effects) 
Model 5: Period and birth 
cohort (fixed effects) plus age 
(random effect)b 
Period 
           
1979 
 
Ref - Ref - Ref - Ref - Ref - 
1986 
 
14.9 (10.2,20.8) 14.4 (9.3,21.1) 15.4 (10.8,21.1) 14.8 (8.2,24) 15.2 (8.4,24.8) 
1994 
 
25.3 (17.5,35.4) 23.5 (14.7,35.6) 25.1 (16.8,36.2) 25.1 (14.6,40.3) 25.9 (15.6,40.6) 
2001 
 
33.3 (23.7,45.7) 29.9 (18.3,46.4) 32.0 (20.8,47.5) 33.0 (20.1,51.8) 32.8 (20.1,51.1) 
2007 
 
22.2 (14.9,31.8) 18.9 (9.8,32.6) 20.6 (11.4,34) 22.0 (12.3,36.4) 22.1 (12.4,36.4) 
Age 

































Birth cohort  




































-0.6 (-4.2,6) -0.9 (-4.3,5.2) 
AIC   116   133   150   128   154   
aCoefficients are back-transformed from log-estimates of fixed effect variables. All models included a subject-specific random term 794 
and a random slope for sampling year. Age and birth cohort variables were divided into quartiles.  795 
bVariables were added to models as random terms to allow for random variation in individuals. 796 
cCoefficients express change for PFOS concentrations in ng/ml across sampling years with 1979 as reference. 797 
dCoefficients express change in PFOS concentrations in ng/ml across age quartiles with the youngest (29-47) as reference. 798 
eCoefficients express change in PFOS concentrations in ng/ml across birth cohort quartiles with the oldest (1925-1934) as reference. 799 
fAkaike’s information criterion. Lower numbers indicate better model fit when comparing models. 800 
  801 
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Fig. S4: APC plots: Longitudinal and cross-sectional organization of concentrations of PFHpA, 802 
PFNA, PFDA and PFHxS (medians for each quartile in each sampling year in ng/ml wet weight). 803 
Further details are provided in the figure legend of Fig. 4 and Section 4.4. of the article. 804 
   805 
PFHpA 







































































































































































Fig. S5: Graphical display of concentrations between 1975 and 2010 from this study ( ) and 806 
other studies: Haug et al., 2007 ( ); Kato et al., 2011 ( ); Olsen et al., 2012 ( ); Schröter-807 
Kermani et al., 2012 ( ). See Section 4.1. of the article for discussion.  808 
 809 
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